VLP Therapeutics – Imagine: Vaccines Without Borders

Publications

[News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience]

2026-02-08T20:20:09-05:002026.02.06|

VLP Therapeutics Japan, Inc. (VLPT Japan) researchers and their colleagues at the National Institutes of Biomedical Innovation, Health and Nutrition (NIBN) in Japan published a paper in iScience online reporting safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base. This research was supported by AMED under Grant Number JP21nf0101627.

[Preprint] Alphavirus replicon particle expressing IL-12 reprograms tumor-associated macrophages and neutrophils and induces anti-tumor immunity

2025-08-12T01:30:12-04:002025.08.12|

VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at the Stanford University School of Medicine posted on August 11 a preprint "Alphavirus replicon particle expressing IL-12 reprograms tumor-associated macrophages and neutrophils and induces anti-tumor immunity" on bioRxiv, a preprint server for biology. Note: Preprints are preliminary reports of work that have not been certified by

[Preprint] Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine

2024-05-19T10:01:32-04:002023.11.01|

VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at the Boston University Chobanian & Avedisian School of Medicine posted on November 1 a preprint "Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine" on bioRxiv, a preprint server for biology. Note: Preprints are preliminary reports of work that have not been certified

[Preprint] A Tetravalent Dengue Virus-like Particle Vaccine Induces High levels of Neutralizing Antibodies and Inhibits Dengue Replication in Non-Human Primates

2024-05-19T10:02:01-04:002023.10.16|

VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at Nagasaki University and the National Institute of Infectious Diseases in Japan posted on October 16 a preprint "A Tetravalent Dengue Virus-like Particle Vaccine Induces High levels of Neutralizing Antibodies and Inhibits Dengue Replication in Non-Human Primates" on bioRxiv, a preprint server for biology. Note: Preprints are

[Preprint] Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals

2024-05-19T10:03:15-04:002023.09.06|

Wataru Akahata of VLP Therapeutics Japan and colleagues posted on September 6 a preprint* "Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals" on medRxiv, a preprint server for health sciences. *Preprints are preliminary reports of work that have not been certified by peer review. They

[News Release] saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern (Nat Commun)

2024-05-19T10:04:44-04:002023.05.23|

Dr. Wataru Akahata of VLP Therapeutics as well as VLPT Japan and colleagues published their findings in the journal Nature Communications: saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern Mai Komori+, Takuto Nogimori+, Amber L. Morey, Takashi Sekida, Keiko Ishimoto, Matthew R. Hassett, Yuji Masuta, Hirotaka Ode, Tomokazu

[Preprint] Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study

2024-05-19T10:05:11-04:002022.11.22|

Wataru Akahata of VLP Therapeutics Japan and colleagues posted on November 22 a preprint* "Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study" on medRxiv, a preprint server for health sciences. *Preprints are preliminary reports of work that have not been certified by peer review. They should

Journal of Virology – 27 September 2017

2017-10-09T00:57:38-04:002017.09.27|

“Envelope-modified tetravalent dengue virus-like particle vaccine: implication for flavivirus vaccine design” Akane Urakamia, Mya Myat Ngwe Tunb, Meng Ling Moib, Atsuko Sakuraia, Momoko Ishikawaa, Sachiko Kunoa, Ryuji Uenoa, Kouichi Moritab and Wataru Akahata   http://jvi.asm.org/content/early/2017/09/21/JVI.01181-17.abstract

Clinical and Vaccine Immunology – July 2017, Volume 24, Issue 7

2017-10-09T00:57:52-04:002017.07.01|

“Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus” Akane Urakami, Atsuko Sakurai, Momoko Ishikawa, Moh Lan Yap, Yevel Flores-Garcia, Yasunari Haseda, Taiki Aoshi, Fidel P. Zavala, Michael G. Rossmann, Sachiko Kuno,a Ryuji Ueno, Wataru Akahata http://cvi.asm.org/content/24/7/e00090-17.full.pdf+html

Go to Top